A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Trial Profile

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs G1T-48 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 06 Mar 2018 Status changed from planning to not yet recruiting.
    • 23 Feb 2018 New trial record
    • 21 Feb 2018 According to a G1 Therapeutics media release, an Investigative New Drug (IND) application to support this trial opened in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top